<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817347</url>
  </required_header>
  <id_info>
    <org_study_id>YH1177-201</org_study_id>
    <nct_id>NCT02817347</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Phase2 Trial to Evaluate the Safety and Efficacy of YH1177 or YH1177-D Otic Soultion in Patients With Otitis Media and Otorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with otitis media presenting with otoscopy-confirmed otorrhea who had&#xD;
      tympanostomy tube insertion or tympanic perforation, to evaluate the safety, tolerability,&#xD;
      and the proportion of patients with cessation of otorrhea after ear-drop administration of&#xD;
      YH1177 or YH1177-D for 14 days and therefore to determine the optimal clinical dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients achieving cessation of otorrhea (grade 0) on Day 15, as evidenced by otoscopy</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with cessation of otorrhea on Day 8 as evidenced by otoscopy</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with cessation of otorrhea on Day 22 as evidenced by otoscopy</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy</measure>
    <time_frame>Day 8</time_frame>
    <description>'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy</measure>
    <time_frame>Day 15</time_frame>
    <description>'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy</measure>
    <time_frame>Day 22</time_frame>
    <description>'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with microbiological eradication at each visit</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with microbiological eradication at each visit</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with microbiological eradication at each visit</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to cessation of otorrhea as recorded by the patient via the patient's diary</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to cessation of otorrhea as recorded by the patient via the patient's diary</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to cessation of otorrhea as recorded by the patient via the patient's diary</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with microbiological eradication(bacterial culture test) by type of randomization pathogen at each visit.</measure>
    <time_frame>Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with microbiological eradication(bacterial culture test) by type of randomization pathogen at each visit.</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with microbiological eradication(bacterial culture test) by type of randomization pathogen at each visit.</measure>
    <time_frame>Day 22</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AUClast</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AUCinf</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tmax</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CL/F</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vd/F</measure>
    <time_frame>pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Otitis Media</condition>
  <condition>Otorrhea</condition>
  <arm_group>
    <arm_group_label>YH1177 (4/0.5%+0.1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1177 (8/1.0%+0.1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1177-D (2/0.25%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>piperacillin 2% + tazobactam 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1177-D (4/0.5%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>piperacillin 4% + tazobactam 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH1177-D (8/1.0%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>piperacillin 8% + tazobactam 1.0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%</intervention_name>
    <arm_group_label>YH1177 (4/0.5%+0.1%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%</intervention_name>
    <arm_group_label>YH1177 (8/1.0%+0.1%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin 2% + tazobactam 0.25%</intervention_name>
    <arm_group_label>YH1177-D (2/0.25%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin 4% + tazobactam 0.5%</intervention_name>
    <arm_group_label>YH1177-D (4/0.5%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin 8% + tazobactam 1.0%</intervention_name>
    <arm_group_label>YH1177-D (8/1.0%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Written Informed Consent A detailed explanation about the study, including the&#xD;
             study purpose and procedures and drug properties, had been provided, and the patient&#xD;
             gave voluntary written informed consent.&#xD;
&#xD;
          -  Target Population Patients with otitis media presenting with otorrhea, as evidenced by&#xD;
             otoscopy, who had tympanostomy tube insertion or tympanic perforation&#xD;
&#xD;
          -  Sex and age Male or female patients 19 years of age or older at screening Women of&#xD;
             childbearing potential (WOCBP) must have 'negative' pregnancy test at screening, and&#xD;
             use an acceptable method of contraception throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excluded Disease&#xD;
&#xD;
               1. Patients diagnosed with otitis media with cholesteatoma, otitis media with&#xD;
                  effusion or otitis externa at screening&#xD;
&#xD;
               2. Patients who had a otologic surgery within 1 year prior to screening (except for&#xD;
                  tympanostomy tube insertion)&#xD;
&#xD;
               3. Subjects who previously had cholesteatoma or mastoid surgery&#xD;
&#xD;
          -  Medical History and Concurrent Disease&#xD;
&#xD;
               1. Patients with complication of labyrinthine fistula at screening&#xD;
&#xD;
               2. Patients with clinically significant medical or mental illness.&#xD;
&#xD;
               3. Patients with infectious disease requiring the use of systemic antimicrobial&#xD;
                  therapy&#xD;
&#xD;
          -  Physical and Laboratory Test Results&#xD;
&#xD;
             a)Clinically significant finding based on the principal investigator/investigator's&#xD;
             opinion.&#xD;
&#xD;
          -  Allergies and Adverse Drug Reactions&#xD;
&#xD;
               1. Known drug allergy (e.g., a history of anaphylaxis or hepatotoxicity)&#xD;
&#xD;
               2. History of hypersensitivity to penicillins or -lactamase inhibitors.&#xD;
&#xD;
               3. History of serious skin reaction such as Stevens-Johnson syndrome or toxic&#xD;
                  epidermal necrosis&#xD;
&#xD;
          -  Prohibited Therapies and/or Medication&#xD;
&#xD;
               1. Patients undergoing a ventilation tube insertion on the day of screening&#xD;
&#xD;
               2. Patients with ventilation tube containing silver oxide or silver salt (e.g.,&#xD;
                  T-type tube)&#xD;
&#xD;
          -  Reproductive status, Women only&#xD;
&#xD;
             a)Woman of childbearing potential (WOCBP) who is unable, or unwilling to use an&#xD;
             acceptable method of contraception during the study&#xD;
&#xD;
          -  Other Exclusion Criteria&#xD;
&#xD;
               1. History of alcohol or drug abuse/addiction within the last 1 year prior to the&#xD;
                  study entry&#xD;
&#xD;
               2. Patient who, in the investigator's opinion, is not suitable for the study for any&#xD;
                  reason (e.g., ECG or hepatitis test results at screening)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chulho jang, M.D Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Chonnam National Universitiy Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National Universitiy Hospital</name>
      <address>
        <city>Gwang-ju</city>
        <state>Chonnam</state>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

